A Phase 3, Randomized, Double-blind, Placebo controlled, Parrallel, Fixed Dose Study to Assess the Efficacy, Safety and Tolerability of NBI 98854 for the treatment of Tardive Dyskinesia
Clinical Trial Grant
Administered By
Neurology, Movement Disorders
Awarded By
Neurocrine Biosciences, Inc.
Start Date
November 1, 2014
End Date
November 9, 2015
Administered By
Neurology, Movement Disorders
Awarded By
Neurocrine Biosciences, Inc.
Start Date
November 1, 2014
End Date
November 9, 2015